



Company Contact:
Jie Du, Ph.D.
President & CEO
JDP THERAPEUTICS, INC.
Email: jiedu@jdptherapeutics.com
www.jdptherapeutics.com

JDP to Present Phase I Clinical Data of JDP-205 at the 2013 AAAAI Annual Conference

BLUE BELL, PENNSYLVANIA, December 21, 2012 – JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, is pleased to announce that the JDP scientific team will be presenting its phase I clinical data on its lead product JDP-205 (a non-sedating antihistamine injection for acute allergic reactions), at the 2013 AAAAI (American Academy of Allergy, Asthma & Immunology) Annual Conference, to be held from February 19, 2013 to February 27, 2013 in San Antonio, TX. Poster Number 96, “A Phase I Assessment of the Safety and Tolerability Profile of Novel Treatments for Acute Allergic Reactions Administered by Intravenous and Intramuscular Injection Formulations” will be presented on Saturday, February 23, 2013 from 9:45-10:45 am, during the Urticaria/Angioedema Session (Session # 2207). Authors will stand by their poster to answer questions during the presentation time.

About JDP-205

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years.

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-

defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.